Guanhao Bio: Net profit in 2021 will increase by 58.14% year-on-year, and sales in the pharmaceutical sector will increase.

　　Guanhao BiologyThe 2021 Annual Report will be released on the evening of April 14performanceReport, the company achieved throughout the yearOperating income489 million yuan, a year-on-year increase of 11.91%; attributable to listed companiesshareholderofnet profit73.687 million yuan, a year-on-year increase of 58.14%; basic earnings per share was 0.28 yuan, a year-on-year increase of 55.56%.

The biomaterials segment achieved operating income of 305 million yuan, an overall increase of 25.51% over 2020. Among them, Guanlang, a new generation of meningeal products, increased by 53.13% compared with the same period of the previous year; In addition, the German intracranial pressure monitoring products represented by the company have been adhering to academic promotion and standardized application for several years, maintaining a rapid growth of 51.75% in 2021, and as the number of users continues to increase, it has laid a good foundation for continued growth in 2022. Through continuous enrichment of product lines, the company’s brand influence in the domestic market has been further enhanced.

It is worth noting that the company’s pharmaceutical product Benvimod cream will be sold in high volume in 2021, achieving an operating income of 29.9274 million yuan. It is understood that the drug was approved as a new drug certificate in May 2019, bringing new hope to the majority of psoriasis patients. At present, Benvimod cream has been officially included in the National Medical Insurance Catalogue and implemented. The inclusion of Benvimod cream in medical insurance will benefit more patients, with sales of 100,000 of the product in 2020 and nearly 400,000 in 2021.In the future, with the acceleration of hospital opening and the academiceducateThe further strengthening of promotional activities, the pharmaceutical sector will have a positive impact on the company’s operating performance.

In addition, the company’s cell segment achieved an operating income of 24.8483 million yuan, a year-on-year increase of 24.46%, achieving both economic and social benefits. The internal organizational structure was further integrated and optimized, and the survival of the fittest mechanism maximized resource allocation, and the segment performance has grown steadily for three consecutive years.

(Article source: ChinasecuritiesReport · China Securities Network)

Article source: China Securities Journal China Securities Network

Responsible editor: 73

Original title: Guanhao Bio: Net profit in 2021 will increase by 58.14% year-on-year, and sales in the pharmaceutical sector will increase